At Soterix Medical Inc., Engineering Serving Humanity means that we're committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.

Latest Press Releases

• Aug 28, 2023Soterix Medical announces Phase-2 trial to test at-home tDCS paired with cognitive training as a therapeutic option for long COVID
• May 08, 2023Soterix Medical Announces Patient Recruitment for Parcel-Guided rTMS Depression Trial
• Oct 13, 2022Soterix Medical Announces award of Fast Track NIH grant to develop a Parcel-Guided software to improve efficacy of rTMS treatment for Depression
• Mar 01, 2022Soterix Medical Improves Safe Mobility Device for Blind Toddlers
• Aug 30, 2021Soterix Medical Announces FDA 510(k) Clearance for the MEGA-TMS System
• Aug 03, 2021Soterix Medical Announces award of DARPA Phase-2 contract to develop a novel modality for information transfer
• Jul 05, 2021Soterix Medical Announces development and testing of HD-tDCS platform for Covid-19 ICU patients in agreement with the Brazilian Government of Paraiba
• May 20, 2021Soterix Medical Announces award of NASA Phase-1 contract to develop a spatial disorientation simulator
• Jan 25, 2021Soterix Medical study to address post-COVID neurological and psychiatric symptoms using at-home neuromodulation and monitoring
• Dec 23, 2020Soterix Medical Announces Expanded Clinical Trials for Alzheimer's disease and Mild Cognitive Impairment
• Jul 07, 2020FDA Grants Soterix Medical IDE Approval for Home-based tDCS-LTE Trial for Depression.
• Apr 06, 2020Soterix Medical Announces FDA 510(k) Clearance for the Neural Navigator System
• May 14, 2019Soterix Medical Announces launch of electro-detox Treatment for Opioid Withdrawal
• Feb 12, 2019Soterix Medical Announces clinical trial of self-administered transcranial Direct Current Stimulation (tDCS) to reduce craving in cocaine addiction
• Nov 27, 2018Soterix Medical Awarded Patent for Advanced Non-Invasive Stimulation Electrodes
• Apr 10, 2018Soterix Medical reports positive results from tDCS-LTE trials for Depression
• Nov 28, 2017Soterix Medical expands South East Asia presence with clinical approval in Singapore for Depression and Fibromyalgia treatment.
• Jul 06, 2017Soterix Medical receives Therapeutic Goods Administration Approval for Major Depression Treatment in Australia
• May 21, 2017Soterix Medical Announces FDA 510(k) Clearance for IontoDC™ System
• Apr 12, 2017Soterix Medical receives ANVISA Medical Device Approval in Brazil for Neuromodulation products including PainX and Depression-LTE treatment
• Sep 27, 2016Soterix Medical Launches PainX tDCS Treatment in Canada with Health Canada Approval
• Jun 14, 2016Soterix Medical Inc. awarded $2.5M NIH grant to run Phase-2 Efficacy Trial to treat Aphasia after Stroke with HD-tDCS
• May 16, 2016Soterix Medical, Inc. Announces tDCS-LTE Depression Treatment Partnership Program for Clinicians and Medical Centers based on its Non-invasive Neuromodulation Platform
• Jan 13, 2016Soterix Medical Launches PainX tDCS Treatment in EU with CE Approval
• Dec 28, 2015Soterix Medical, Inc. Receives CE Mark Approval for 1x1 tDCS Depression Therapy
• Mar 31, 2015Soterix Medical Inc announces the launch of the mini-CT platform for Remote-Supervised Neuromodulation
• Jan 04, 2015Soterix Medical Inc. announces “BETTER” Clinical Trial for Treatment of Bipolar Depression
• Nov 19, 2014Soterix Medical Awarded Patent for Limited Energy Neuromodulation
• Apr 02, 2014Soterix Medical Awarded Another Patent for High-Definition transcranial Direct Current Stimulation Platform
• Mar 24, 2014Beckman Institute Initiates Study Using Soterix Medical HD-tDCS for Fluid Intelligence: $12.7million in Funding Through IARPA
• Dec 01, 2013Soterix Medical Inc. , Rogue Resolutions Ltd., and neuroConn GmbH announce MOBILE neuromodulation platform at NYCneuromodulation 2013 conference
• Oct 28, 2013Soterix Medical Inc. announces Phase 3 Clinical Trial for Depression comparing tDCS-LTE against antidepressant drug (Escitalopram)
• Aug 01, 2013Soterix Medical Awarded Patent For Optimized High-Definition transcranial Direct Current Stimulation
• Jul 24, 2013Soterix Medical, one of ten finalists for B.R.A.I.N. Prize, was announced by Israel Brain Technologies (IBT)
• May 31, 2013Soterix Medical Inc. Announces the Launch of its New transcranial Direct Current Stimulation with Limited Total Energy (tDCS-LTE) Series of Products for Non-Invasive Neuromodulation
• Feb 19, 2013Soterix Medical Inc. reports positive results from High-Definition tDCS Fibromyalgia Trial at Harvard Medical School
• Jan 14, 2013Soterix Medical announces completion of Stroke- Aphasia Trial
• Oct 27, 2012Soterix Medical Inc. announces a land-mark study on generation of “peak” brain plasticity by HD-tDCS
• Oct 25, 2012Soterix Medical Inc. receives FDA IDE for Clinical Trial on Use of High-Definition transcranial Direct Current Stimulation (HD-tDCS) to improve IQ in pediatric Down syndrome.
• Sep 23, 2012The National Institute of Health awards the Burke Medical Research Institute $3 Million to study transcranial Direct Current Stimulation (tDCS) in conjunction with robotic training in chronic stroke.
• Jun 12, 2012Soterix Medical Inc. Announces clinical trial of High-Definition transcranial Direct Current Stimulation (HD-tDCS) for pediatric epilepsy
• Jun 10, 2012Soterix Medical Inc. Announces Multi-Center transcranial Direct Current Stimulation (tDCS) Depression Trial
• Jul 25, 2011Soterix Medical Inc. Announces clinical trial of High-Definition transcranial Direct Current Stimulation (HD-tDCS) for stroke aphasia
• Jun 27, 2011Soterix Medical Inc. Announces clinical trial of High-Definition transcranial Direct Current Stimulation (HD-tDCS) for Fibromyalgia